• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

BIO CEO & Investor Conference 2008 Presenter Profiles

Posted on: Monday, 11 February 2008, 18:00 CST

The BIO CEO & Investor Conference 2008 takes place February 11, 2008 - February 13, 2008 in New York. Listed below are BIO CEO & Investor Conference 2008 presenter profiles.

For in-depth information about BIO CEO & Investor Conference 2008, visit http://ceo.bio.org/opencms/ceo/2008/.

Business Wire is the official news wire for the BIO CEO & Investor Conference 2008. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Company:

Affymax

Ticker Symbol & Exchange:

Nasdaq: AFFY

Investor Relations Contact:

Sylvia Wheeler

Phone:

650-812-8861

Web:

www.affymax.com

Date of Presentation:

February 12, 2008 at 2:00 p.m.

Affymax is a biopharmaceutical company that is developing a pipeline of synthetic peptide-based drug candidates against clinically validated targets for the treatment of kidney diseases and cancer. Affymax's objective is to discover, develop and commercialize novel therapeutics addressing large unmet medical needs. In August 2001, a collaboration of several venture firms created Affymax as an independent company--a spin-out from GlaxoSmithKline. Affymax has leveraged its foundation to become a developer of peptide drugs.

Hematide, our lead product, is a synthetic peptide-based erythropoiesis-stimulating agent (ESA) in clinical development for the treatment of anemia. Hematide is currently entering Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase 1 clinical trial for the treatment of anemia in cancer patients.

Anemia associated with chronic renal failure and cancer is estimated to be a $12 billion worldwide market.

Company:

Array BioPharma Inc.

Ticker Symbol & Exchange:

Nasdaq: ARRY

Investor Relations Contact:

Tricia Haugeto

Phone:

303-386-1193

Web:

www.arraybiopharma.com

Date of Presentation:

Tuesday, February 12, 2008 at 11 a.m.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory diseases and pain. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at large market opportunities. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Company:

Avigen, Inc.

Ticker Symbol & Exchange:

Nasdaq: AVGN

Investor Relations Contact:

Michael Coffee

Phone:

510-748-7372

Web:

www.avigen.com

Date of Presentation:

Wednesday, February 13, 2008

Avigen is a biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. Avigen's strategy is to complete the requirements of clinical development for each of the candidates in its product pipeline, and continue to look for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing, with the goal of becoming a fully integrated commercial biopharmaceutical company committed to its small molecule and biologics neurology products. The company currently has in development AV650 for neuromuscular spasm and spasticity and AV411 for neuropathic pain. Additionally, the company has in development AV513, a compound for the treatment of hemophilia A and B.

Company:

BioSante Pharmaceuticals, Inc.

Ticker Symbol & Exchange:

NASDAQ: BPAX

Investor Relations Contact:

Phillip Donenberg

Phone:

847-478-0500 ext 101

Web:

www.biosantepharma.com

Date of Presentation:

February 11, 2008

BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver estradiol and testosterone. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD) and Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology.

Company:

Ceregene, Inc.

Investor Relations Contact:

Jeffrey Ostrove, Ph.D.

Phone:

858-458-8808

Web:

www.ceregene.com

Date of Presentation:

2/12/08, 12:30 p.m.

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1/2 studies for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which recently completed enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-130 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001 and is based in San Diego, California.

Company:

Cleveland BioLabs, Inc.

Ticker Symbol & Exchange:

Nasdaq: CBLI

Investor Relations Contact:

Rachel Levine

Phone:

646-284-9439

Web:

www.cbiolabs.com

Date of Presentation:

2/12/2008

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and ischemic diseases. The Company has two late-stage compounds in development: Protectan CBLB502, a radioprotectant, for which the Company expects to file an NDA in 2009 for defense applications and will start human trials for medical uses in 2008; and Curaxin CBLC102 for hormone refractory prostate cancer, which is completing a Phase II trial. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.

Company:

Curidium Medica

Ticker Symbol & Exchange:

LSE: CUR

Investor Relations Contact:

Paula Schwartz

Phone:

917-322-2216

Web:

http://www.curidium.com

Date of Presentation:

February 12, 2008

Curidium, a personalized medicine company, identifies companion diagnostics and develops targeted medicines, and is focused initially on CNS diseases. Its proprietary gene expression analysis technology, Homomatrix®, identifies distinct patient subgroups in heterogeneous diseases, leading to the development of diagnostic tools to identify these groups. Curidium has developed PsychINDx™, a diagnostic blood test, that identifies patient subgroups in schizophrenia/bipolar disorder. Curidium expects the test will be used to improve clinical trial success rates and ultimately, to select the most appropriate therapy for individual patients. In 12/07, Curidium signed a strategic partnership in major depressive disorder with Takeda Research Investment, Inc.

Company:

Cyclacel Pharmaceuticals, Inc.

Ticker Symbol & Exchange:

CYCC

Investor Relations Contact:

Corey Sohmer

Phone:

908-517-7330

Web:

www.cyclacel.com

Date of Presentation:

2/12/2008

Cyclacel is a diversified biopharmaceutical business dedicated to the discovery, development and commercialization of novel, targeted drugs to treat cancer. Cyclacel's strategy is focused on leading edge therapeutic management of cancer patients based on a portfolio of three medicines marketed by its ALIGN subsidiary and a deep development pipeline. Three orally-available drugs are in clinical development: sapacitabine (in two randomized Phase 2 studies for the treatment of elderly acute myeloid leukemia and cutaneous T-cell lymphoma); seliciclib (in two randomized Phase 2 studies for the treatment of lung and nasopharyngeal cancers) and CYC116 (in Phase 1 in patients with solid tumors).

Company:

GW Pharmaceuticals plc

Ticker Symbol & Exchange:

AIM: GWP

Investor Relations Contact:

Justin Gover

Phone:

(44) 207 291 0555

Web:

www.gwpharm.com

Date of Presentation:

February 12, 2008

GW is a public company listed on AIM, a market of the London Stock Exchange. GW researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular pain and other neurological symptoms. GW's lead product, Sativex®, is approved and marketed in Canada for the treatment of cancer pain and neuropathic pain in Multiple Sclerosis. Sativex is currently in Phase III trials in both Europe and the United States. GW has signed license agreements with Otsuka, Bayer HealthCare and Almirall. The company also has a pipeline of cannabinoids targeting CNS, oncology and metabolic disorders.

Company:

Inspire Pharmaceuticals

Ticker Symbol & Exchange:

ISPH

Investor Relations Contact:

Jenny Kobin

Phone:

919 941-9777

Web:

www.inspirepharm.com

Date of Presentation:

February 13, 2008; 11:00 a.m.

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite® (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a registered trademark owned by InSite Vision Incorporated.

Company:

Lev Pharmaceuticals, Inc.

Ticker Symbol & Exchange:

OTCBB: LEVP

Investor Relations Contact:

Jason Tuthill

Phone:

(212) 850-9130

Web:

www.levpharma.com

Date of Presentation:

February 12, 2008

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's lead product candidate, Cinryze™ (C1 inhibitor), is being developed as a replacement therapy for both the acute and prophylactic treatment of Hereditary Angioedema (HAE), also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze has been granted orphan drug status for the acute and prophylactic treatment of HAE, potentially securing, upon approval, market exclusivity for seven years. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

Company:

Neurotez, Inc.

Ticker Symbol & Exchange:

Private

Investor Relations Contact:

Eugene Oliva

Phone:

908-998-1340

Web:

www.neurotez.com

Date of Presentation:

2/13/2008

Neurotez, is a development-stage private company operating from NJ. Our mission is to become global leaders in CNS biotechnology, building a platform which will span activities from drug discovery to proof of concept clinical trials. Neurotez proposes to undertake the clinical development of Leptin to further its commercialization as a therapy for Alzheimer's disease by leveraging existing data from preclinical and animal studies along with extensive clinical data to proceed directly to an IND filing.

Company:

Pharmacopeia, Inc.

Ticker Symbol & Exchange:

PCOP

Investor Relations Contact:

Amy P. Sharpless

Phone:

609-452-3643

Web:

www.pharmacopeia.com

Date of Presentation:

February 12, 2008 at 2:00 p.m.

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. Pharmacopeia has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals.

Company:

Redpoint Bio Corporation

Ticker Symbol & Exchange:

OTCBB: RPBC

Investor Relations Contact:

Paula Schwartz

Phone:

917-322-2216

Web:

http://www.redpointbio.com

Date of Presentation:

February 13, 2008

Redpoint Bio is leveraging recent discoveries in the molecular biology of taste to discover and develop new taste modulators for use in healthier food & beverages and pharmaceutical formulations. The food and beverage program is focused on identifying novel flavors that improve the tastes of existing ingredients and enable the development of better-tasting, healthier products. In 2007, Redpoint signed key R&D collaborations with The Coca Cola Company and Givaudan.

Redpoint's pharmaceutical program uses a biochemical approach aimed at suppressing the bitterness of medicines, providing the potential to expand the range of formulation options and increase patient compliance.

Company:

Resverlogix Corp.

Ticker Symbol & Exchange:

TSX: RVX

Investor Relations Contact:

Sarah Zapotichny

Phone:

403-254-9252

Web:

www.resverlogix.com

Date of Presentation:

February 12, 2008

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ program is the Company's primary focus, which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. For further information please visit www.resverlogix.com

Company:

VioQuest Pharmaceuticals

Ticker Symbol & Exchange:

VQPH, OTCBB

Investor Relations Contact:

Brian Lenz, CFO

Phone:

908-766-4400

Web:

www.vioquestpharm.com

Date of Presentation:

2/12/2008

VioQuest Pharmaceuticals is developing novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest's oncology portfolio includes: VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt phosphorylation, which is currently being tested in Phase I clinical trials in both solid and hematological malignancies; Lenocta (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B, which is currently in a Phase IIa trial for solid tumors; and Xyfid (1% topical uracil), which is expected to enter Phase II development in 2008 for the treatment and prevention of Hand-Foot Syndrome, a common side effect from certain chemotherapy treatments.

Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.

Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow [at] businesswire.com.

Source: Business Wire

More News in this Category